Investor Presentaiton

sanofi SP0273 reactogenicity compares favorably to other mRNA trial 20 20 15 10 10 % Any Grade 3 solicited injection site reactions 5 8 Reactogenicity in 18-64 years 3 0 0 SP0273 Fluzone Flublok mRNA Flu QIV Standard Dose 7 20 20 S 10 % Any Grade 3 solicited systemic reactions mRNA-1010 Moderna¹ 5 15.8 SP0273 results Reactogenicity higher compared to current licensed flu vaccines - Systemic reactions lower than in a comparator mRNA vaccine in a different trial¹ 0 0 0 SP0273 Fluzone Flublok mRNA Standard Flu QIV Dose mRNA-1010 Moderna¹ 1. Data collected by Moderna in 18-49 years volunteers in a separate phase 2 trial. Moderna Third Annual Vaccines Day March 24th, 2022. DISCLAIMER: data from separate studies should be interpreted with care. 50 Vaccines Investor Event

View entire presentation